Discover this groundbreaking webinar delving into the latest insights from the Cross-Company Abuse Liability Council (CCALC) and The Food and Drug Administration (FDA) in drug development and clinical evaluation of human drug abuse and dependence potential. This...
OVERLAND PARK, Kan.–(BUSINESS WIRE)–Dr. Vince Clinical Research (DVCR), a full-service Phase I-II contract research organization (CRO) announced a new solution to conduct renal and hepatic impairment studies. The solution leverages trusted relationships...
Most drugs are eliminated from the body through some combination of vital organs, such as the small intestine, liver and/or kidneys. The impaired function of either the liver or the kidney can significantly impact a drug’s pharmacokinetics (PK), influencing its...
Dr. Vince Clinical Research (DVCR), a full-service clinical research organization (CRO), today announced the first dosing in Cingulate Therapeutics’ CTx-1301 Phase III dose-optimization onset and duration laboratory classroom study. This study is taking place in...
Strategic collaboration amplifies accessibility to Clario’s Early Precision QT (EPQT) methodology, enabling biopharmaceutical firms to secure more accurate and cost-efficient cardiac safety data in early clinical development stages. Meticulous multi-stage evaluation...
Recent Comments